Grifols SA (GRFS)
NASDAQ:GRFS
Top Page
Grifols SA
(NASDAQ:GRFS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$8.50
▼(-3.19% Downside)
Action:ReiteratedDate:03/28/26
The score is held back primarily by weak technicals (price below key moving averages with negative momentum) and balance-sheet risk from elevated leverage. These are partially offset by improving profitability/cash generation that supports deleveraging and a moderate valuation with a small dividend yield.
Positive Factors
Vertical integration (plasma supply chain)
Owning plasma collection centers plus in-house fractionation and manufacturing creates a durable competitive advantage: secures raw-material access, improves yield control and quality, and raises barriers to entry versus pure-play distributors, supporting consistent supply and margins over time.
Negative Factors
High leverage and large debt burden
Elevated absolute debt restricts strategic flexibility: servicing and refinancings will consume cash and limit capacity for M&A or capex, making the company sensitive to interest-rate moves and credit-market conditions despite recent deleveraging trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration (plasma supply chain)
Owning plasma collection centers plus in-house fractionation and manufacturing creates a durable competitive advantage: secures raw-material access, improves yield control and quality, and raises barriers to entry versus pure-play distributors, supporting consistent supply and margins over time.
Read all positive factors
Grifols SA (GRFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.80B
Dividend Yield1.56%
Average Volume (3M)838.61K
Price to Earnings (P/E)14.0
Beta (1Y)1.03
Revenue Growth9.45%
EPS Growth167.00%
CountryUS
Employees23,833
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.17
Shares Outstanding261,425,100
10 Day Avg. Volume676,181
30 Day Avg. Volume838,612
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.03
Price to Sales (P/S)0.75
P/FCF Ratio7.21
Enterprise Value/Market Cap2.24
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda9.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.02
Revenue Forecast (FY)$9.03B
Grifols SA Business Overview & Revenue Model
Company Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience divi...
How the Company Makes Money
Grifols makes money primarily by selling plasma-derived medicines and services, complemented by revenue from diagnostic and transfusion-related products. Its largest revenue stream comes from plasma-derived therapies (biopharma), where the company...
Grifols SA Key Performance Indicators (KPIs)
Any
Revenue by Business Type
Breaks down sales between plasma‑derived therapies, diagnostics, hospital products and other units so you can see which lines deliver margins, recurring cash flow, and growth. A large share from recurring plasma products usually means stable revenue but depends on donor supply and regulatory approvals; expanding diagnostics or hospital businesses can diversify risk but may be more cyclical and require upfront investment.
Breaks down sales between plasma‑derived therapies, diagnostics, hospital products and other units so you can see which lines deliver margins, recurring cash flow, and growth. A large share from recurring plasma products usually means stable revenue but depends on donor supply and regulatory approvals; expanding diagnostics or hospital businesses can diversify risk but may be more cyclical and require upfront investment.
Data provided by:
The Fly
The FlyGrifols SA Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call highlights Grifols' robust financial performance, with significant revenue growth, improved adjusted EBITDA, and strengthened free cash flow. The company has made progress in deleveraging and gaining market share, particularly in the immunoglobulins franchise. However, challenges such as pricing pressures in China and exchange rate headwinds persist, along with a delay in regulatory approval for fibrinogen in the U.S. Despite these challenges, the overall sentiment leans towards positive, given the strong financial and operational metrics.Positive Updates
Strong Revenue Growth
Grifols achieved revenue of EUR 5.5 billion year-to-date, representing a year-over-year increase of 7.7% and 10.5% like-for-like after adjustments, both at constant currency.
Negative Updates
Challenges in China Market
Albumin volumes faced ongoing pricing pressure in China due to government-imposed cost controls, resulting in a contraction of 4.5% for the quarter and 3.9% year-to-date, both at constant currency.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Revenue Growth
Grifols achieved revenue of EUR 5.5 billion year-to-date, representing a year-over-year increase of 7.7% and 10.5% like-for-like after adjustments, both at constant currency.
Read all positive updates
Company Guidance
During the third quarter of 2025, Grifols demonstrated strong operational and financial performance, achieving revenue of EUR 5.5 billion, marking a year-over-year increase of 7.7% at constant currency. The company reported a third-quarter adjusted EBITDA of EUR 482 million, contributing to a year-to-date adjusted EBITDA of EUR 1,358 million, which is an 11.2% increase from the previous year. Free cash flow pre-M&A and pre-dividends improved significantly by EUR 257 million year over year, totaling EUR 188 million. Despite challenges like exchange rate headwinds and the Inflation Reduction Act, Grifols maintained a leverage ratio of 4.2x by the end of Q3, nearly a 1x improvement from the prior year. The company's immunoglobulins franchise led growth, with the biopharma portfolio growing 10.9% in Q3. Grifols revised its full-year free cash flow guidance to EUR 400-425 million, reflecting the company's focus on financial discipline and resilience amidst a complex global environment.Grifols SA Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
43
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.23B | 7.21B | 6.59B | 6.06B | 4.93B |
| Gross Profit | 2.58B | 2.79B | 2.48B | 2.21B | 1.96B |
| EBITDA | 1.62B | 1.48B | 1.17B | 1.19B | 944.03M |
| Net Income | 386.13M | 156.92M | 42.32M | 185.03M | 188.73M |
Balance Sheet | |||||
| Total Assets | 19.75B | 21.41B | 20.99B | 21.23B | 19.23B |
| Cash, Cash Equivalents and Short-Term Investments | 824.65M | 1.00B | 646.04M | 580.24M | 2.69B |
| Total Debt | 8.74B | 10.09B | 11.02B | 9.75B | 10.17B |
| Total Liabilities | 12.13B | 12.80B | 13.48B | 13.25B | 11.92B |
| Stockholders Equity | 5.27B | 5.88B | 5.37B | 5.65B | 5.52B |
Cash Flow | |||||
| Free Cash Flow | 751.14M | 530.80M | -91.63M | -386.43M | 349.60M |
| Operating Cash Flow | 1.01B | 902.17M | 218.69M | -10.87M | 596.98M |
| Investing Cash Flow | -556.15M | 886.67M | -394.72M | -1.98B | -854.15M |
| Financing Cash Flow | -508.12M | -1.36B | 171.49M | -173.49M | 2.30B |
Grifols SA Technical Analysis
Neutral
8.78
Price Trends
8.65
Negative
8.80
Negative
9.24
Negative
Market Momentum
-0.11
Negative
55.11
Neutral
87.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Neutral. The current price of 8.78 is above the 20-day moving average (MA) of 7.90, above the 50-day MA of 8.65, and below the 200-day MA of 9.24, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 87.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRFS.
Grifols SA Risk Analysis
Grifols SA disclosed 53 risk factors in its most recent earnings report. Grifols SA reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grifols SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $172.31B | 17.94 | 41.01% | 2.52% | 2.51% | 1682.88% | |
71 Outperform | $188.57B | 22.84 | 96.65% | 3.00% | 10.56% | 88.13% | |
71 Outperform | $120.56B | 15.61 | 39.27% | 4.11% | -0.22% | ― | |
69 Neutral | $113.56B | -31.42 | 14.71% | 4.58% | -9.32% | 120.62% | |
67 Neutral | $113.76B | 13.19 | 37.19% | 3.41% | 7.51% | 132.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.80B | 14.03 | 7.56% | 1.56% | 9.45% | 167.00% |
* Healthcare Sector Average
GRFS
Grifols SA
8.39
1.55
22.66%
AMGN
Amgen
349.81
67.57
23.94%
BMY
Bristol-Myers Squibb
59.20
8.02
15.67%
GILD
Gilead Sciences
141.54
39.02
38.06%
GSK
GlaxoSmithKline
57.37
24.21
73.01%
SNY
Sanofi
47.14
-2.49
-5.02%
Grifols SA Corporate Events
Grifols Weighs U.S. IPO of Biopharma Subsidiary to Support Self-Sufficiency Strategy
Mar 24, 2026
On March 24, 2026, Grifols announced that its board has begun evaluating a potential U.S. initial public offering of a portion of the shares of its subsidiary that heads its U.S. Biopharma business, as part of its self-sufficiency programs for pla...
Grifols Doubles 2025 Profit and Secures Key Plasma and Fibrinogen Approvals
Feb 26, 2026
Grifols reported its full-year 2025 results on February 26, 2026, posting revenues of €7.52 billion, up 7.0% at constant currency, largely driven by robust Biopharma growth and strong demand for immunoglobulins. Adjusted EBITDA rose to ̈́...
Grifols Swings to Profit as Board Signs Off 2025 Annual Accounts
Feb 26, 2026
On 25 February 2026, Grifols’ board of directors approved and signed the individual audited financial statements for the year ended 31 December 2025, asserting that they present a true and fair view of the company’s net worth, financia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.